Nodal marginal zone B cell lymphoma

From WikiMD's Medical Encyclopedia

Revision as of 03:19, 29 February 2024 by Prab (talk | contribs) (CSV import)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Nodal marginal zone B cell lymphoma (NMZL) is a rare type of non-Hodgkin lymphoma that originates from B cells in the marginal zone of lymph nodes. It is characterized by slow growth and typically presents with lymphadenopathy, or swollen lymph nodes.

Epidemiology

NMZL is a rare disease, accounting for less than 2% of all non-Hodgkin lymphomas. It is more common in adults, with a median age of diagnosis in the sixth decade of life. There is no known gender predilection.

Pathogenesis

The exact cause of NMZL is unknown. However, it is believed to originate from B cells in the marginal zone of lymph nodes. These cells undergo malignant transformation, leading to the development of lymphoma. Some studies suggest a possible role of chronic inflammation or autoimmune disorders in the pathogenesis of NMZL.

Clinical Features

Patients with NMZL typically present with painless lymphadenopathy. Other symptoms may include fever, night sweats, and weight loss, collectively known as B symptoms. Some patients may also have splenomegaly, or an enlarged spleen.

Diagnosis

The diagnosis of NMZL is based on the histological examination of a lymph node biopsy. The lymphoma cells typically have a monocytoid appearance and are located in the marginal zone of the lymph node. Immunohistochemistry shows that the cells express B cell markers such as CD20 and CD79a.

Treatment

The treatment of NMZL depends on the stage and symptoms of the disease. For patients with localized disease, radiotherapy may be used. For those with advanced disease, chemotherapy with or without immunotherapy is typically recommended. The most commonly used chemotherapy regimen is R-CHOP, which includes rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.

Prognosis

The prognosis of NMZL is generally good, with a 5-year survival rate of over 70%. However, the disease often has a relapsing-remitting course, and long-term follow-up is necessary.

Stub icon
   This article is a hematology stub. You can help WikiMD by expanding it!




Stub icon
   This article is a medical stub. You can help WikiMD by expanding it!



Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes


Ad. Transform your life with W8MD's

GLP-1 weight loss injections special from $29.99 with insurance

Advertise on WikiMD


WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.